Drug hypersensitivity, in vitro tools, biomarkers, and burden with COVID‐19 vaccines. Issue 12 (8th August 2022)

• Record Type: Journal Article
• Authors: Palomares, Francisca; Paris, Juan L.; Labella, Marina; Doña, Inmaculada; Mayorga, Cristobalina; Torres, María José
• Is Part Of: Allergy. Volume 77:Issue 12(2022)
• Page Start: 3527
• Page End: 3537
• Publication Date: 2022-08-08
• Subjects: biomarkers -- COVID‐19 -- hypersensitivity reactions -- in vitro test -- vaccines; Allergy -- Periodicals; 616.97
• DOI: 10.1111/all.15461
• Languages: English
• ISSNs: 0105-4538

Abstract

Abstract: Hypersensitivity reactions to drugs are increasing worldwide. They display a large degree of variability in the immunological mechanisms involved, which impacts both disease severity and the optimal diagnostic procedure. Therefore, drug hypersensitivity diagnosis relies on both in vitro and in vivo assessments, although most of the methods are not well standardized. Moreover, several biomarkers can be used as valuable parameters for precision medicine that provide information on the endotypes, diagnosis, prognosis, and prediction of drug hypersensitivity development, as well on the identification of therapeutic targets and treatment efficacy monitoring. Furthermore, in the last 2 years, the SARS‐CoV‐2 (severe acute respiratory syndrome‐coronavirus) pandemic has had an important impact on health system, leading us to update approaches on how to manage hypersensitivity reactions to drugs used for its treatment and on COVID‐19 (Coronavirus disease) vaccines used for its prevention. This article reviews recent advances in these 3 areas regarding drug hypersensitivity: in vitro tools for drug hypersensitivity diagnosis, recently identified biomarkers that could guide clinical decision making and management of hypersensitivity reactions to drugs and vaccines used for COVID‐19.